CClinicalTrials.gg
CompletedNCT06044363Updated Oct 23, 2023

Satir Model for Self-esteem, Mental Health, and Family Function Among Individuals With Substance Use Disorders

An interventional study of Satir group in Drug Abuse, Self Esteem and Mental Health Wellness 1, sponsored by Hong Kong Metropolitan University. Completed at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-10-23.

Sponsored by Hong Kong Metropolitan University · Not applicable, Interventional, and Supportive care

Phase
Not applicable
Study type
Interventional
Enrollment
45
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Self-esteem and family functioning are associated with mental health and success of drug treatment among individuals with substance use disorders (SUD). The Satir model aims to empower individuals to explore their internal resources, address emotional issues, shift coping strategies, enhancing self-esteem, and develop healthier ways of relating to themselves and others. It offers a range of techniques to enhance self-esteem, challenging negative belief systems, and promote personal growth. The aim of the study is to investigate the acceptability and preliminary efficacy of the Satir model on self-esteem, mental health, and family function among individuals with SUD in China. The study will adopt a mixed-method approach. The quantitative phase will employ a randomized control trial (RCT) utilizing a pre-post study design. The qualitative phase will involve conducting semi-structured individual interviews.The data will be analyzed by using SPSS software package (IBM SPSS statistics version 26.0). The individual-interview will be analyzed by using the six-phase thematic analysis. The study has the potential to advance knowledge in the field of drug rehabilitation interventions, inform evidence-based practice, and improve the wellbeing and outcomes of individual with SUD. It can contribute to the ongoing efforts to address the complex challenges associated with substance use and support individual on their trajectory to recovery.

02

Conditions studied

  • Drug Abuse
  • Self Esteem
  • Mental Health Wellness 1
  • Family Dysfunction
03

In context

Substance-Related Disorders

2,124 studies on the registry are indexed under Substance-Related Disorders; 393 are open to participants now.

This study's enrollment of 45 is below the median of 108 across 1,727 interventional studies indexed under Substance-Related Disorders.

Browse Substance-Related Disorders studies →

Lead sponsor

Hong Kong Metropolitan University is the lead sponsor of 56 studies on the registry; 31 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. aged 18 or above;
  2. are able to speak, read, and write Chinese;
  3. are willing to participate in the study and share their experience of the intervention with the research group;
  4. have informed consent to participate in the study.

Exclusion criteria

Exclusion Criteria:

  1. have been diagnosed with severe mental illnesses, such as schizophrenia, mania, antisocial personality disorder;
  2. have a diagnosed memory and cognitive impairment;
  3. are undergoing psychotherapeutic or psychopharmacologic treatment;
  4. are participating in similar studies.
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
45 participants (actual)

Study arms

  • Experimental
    Satir group

    Participants in the intervention group will receive a 10-session Satir model intervention.

    Other: Satir group

  • No intervention
    Control group

    Participants in the control group will receive care as usual.

Interventions

  • OtherSatir group

    Participants in the intervention group will receive a 10-session, 3-hour/session intervention that spans over a period of five days (2 sessions/day). The intervention program will be conducted on specific weekends, with a gap of 1 to 2 weeks. The total duration of the intervention will be 30 hours.

06

What researchers measure

Primary outcomes

  1. Self-esteem

    The changes of participants' self-esteem will be assessed by using the Chinese version of Rosenberg self-esteem scale. Total scores range from 10 to 40, with higher scores representing lower self-esteem.

    Time frame: Through study completion, an average of two months

Secondary outcomes

  1. Adult attachment

    Adult attachment will be assessed by using Adult attachment scale (AAS).The scale consists of 18 items scored on a 5 point likert-type scale. It measures adult attachment styles named "Secure", "Anxious" and "Avoidant".

    Time frame: Through study completion, an average of two months

  2. Coping style

    Coping style via Chinese version of simplified coping style questionnaire (SCSQ). It consists of 20 items referring to different ways of coping, with a total score range from 0 to 60. Two subscales are active coping and passive coping.

    Time frame: Through study completion, an average of two months

  3. Self-efficacy

    self-efficacy will be assessed by the general self-efficacy scale (GSES). The total score range from 10 to 40. Higher scores indicate higher perceived general self-efficacy

    Time frame: Through study completion, an average of two months

  4. Meaning in life

    Meaning in life will be assessed by using the Chinese version of meaning in life questionnaire (MLQ). It includes 10 items with a total score range from 10 to 70. It consists two subscales: MLQ Presence (MLQ-P) and Search (MLQ-S), each of them containing five items. The internal consistency of MLQ is 0.819.

    Time frame: Through study completion, an average of two months

  5. Resilience

    Resilience will be assessed via. the 25-item Connor-Davidson Resilience Scale (CD-RISC-25). The items are evaluated on a five-point likert scale ranging from 1 to 4. These ratings result in a number between 0-100, and higher scores indicate higher resilience.

    Time frame: Through study completion, an average of two months

  6. Positive and negative affect scale

    Positive and negative affect scale via Positive and negative affect scale (PANAS). This brief scale is comprised of 20 items, with 10 items measuring positive affect (e.g., excited, inspired) and 10 items measuring negative affect (e.g., upset, afraid). Scores can range from 10 to 50 for both the Positive and Negative Affect, with the lower scores representing lower levels of Positive/Negative Affect and higher scores representing higher levels of Positive/Negative Affect.

    Time frame: Through study completion, an average of two months

  7. Drug craving

    Drug craving will be assessed via the drug craving scale. It measures five dimensions of substance craving, including (1) prizing substance craving; (2) reflecting substance craving; (3) social substance craving; (4) negative substance craving; and (5) eliminating substance craving. The items are evaluated on a seven-point likert scale ranging from 1(strongly disagree) to 7 (strongly agree),

    Time frame: Through study completion, an average of two months

  8. Motivation to abstain from drugs

    Motivation to abstain from drugs will be assessed via the motivation to abstain from drugs. It includes 31 items, The items are evaluated on a five-point likert scale ranging from 1(strongly disagree) to 5 (strongly agree), with higher score indicates higher level of motivation to abstain from drugs.

    Time frame: Through study completion, an average of two months

  9. Family function

    Family function via the Chinese version of the 60-item McMaster Family Assessment Device (FAD). It includes seven subscale: problem solving, communication, roles, affective responsiveness, affective involvement, behavior control, and general function. The higher the overall score, the worse the level of family function.

    Time frame: Through study completion, an average of two months

07

Study locations

1 site
  • Fangqiang compulsory isolation detoxification center
    Yancheng, Jiangsu 224000, China
08

References and documents

Individual participant data

Plan to share: Yes — The relevant anonymized participant-level data, full dataset, technical appendix, and statistical code are available on reasonable request. The approval from the Principal Investigator for the purpose of data use is required.

Supporting information: Sap, Icf, Csr

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 23, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06044363
Lead sponsor
Hong Kong Metropolitan University
Responsible party
Dr Polly MA Haixia (Assistant Professor, Hong Kong Metropolitan University) — Principal investigator
First posted
Sep 21, 2023
Start date
Sep 1, 2023
Primary completion
Sep 9, 2023
Completion
Sep 30, 2023
Last update
Oct 23, 2023

Study contacts

Haixia Ma, PhD
principal investigator · Hong Kong Metropolitan University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion